Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.98
+0.06 (1.01%)
At close: Dec 5, 2025, 4:00 PM EST
5.96
-0.02 (-0.33%)
After-hours: Dec 5, 2025, 7:36 PM EST

Company Description

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.
Ardelyx logo
Country United States
Founded 2007
IPO Date Jun 19, 2014
Industry Biotechnology
Sector Healthcare
Employees 395
CEO Michael Raab

Contact Details

Address:
400 Fifth Avenue, Suite 210
Waltham, Massachusetts 02451
United States
Phone 510 745 1700
Website ardelyx.com

Stock Details

Ticker Symbol ARDX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001437402
CUSIP Number 039697107
ISIN Number US0396971071
SIC Code 2834

Key Executives

Name Position
Michael G. Raab President, Chief Executive Officer and Director
Elizabeth A. Grammer Esq. Chief Legal and Administrative Officer and Secretary
Dr. Laura A. Williams M.D., M.P.H. Chief Patient Officer
Mike Kelliher Chief Business Officer
Sue Hohenleitner Chief Financial Officer
Joseph Reilly Senior Vice President of Finance and Principal Accounting Officer
Caitlin Lowie Vice President of Corporate Communications and Investor Relations
James P. Brady Chief Human Resources Officer
Eric Duane Foster Chief Commercial Officer
Dr. Edward Conner M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 24, 2025 144 Filing
Nov 20, 2025 144 Filing
Nov 20, 2025 144 Filing
Nov 20, 2025 144 Filing
Nov 20, 2025 144 Filing
Nov 20, 2025 144 Filing
Nov 20, 2025 144 Filing
Nov 14, 2025 SCHEDULE 13G/A Filing
Nov 3, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Nov 3, 2025 S-8 Securities to be offered to employees in employee benefit plans